Navigating the European Bio-Startup Ecosystem: A Founder’sGuide

The European bio-startup scene is a mosaic of invention, challenge, and opportunity where entrepreneurial spirit meets modern science in settings buzzing with activity. Over $54 billion financed over 1,936 deals in just the first half of 2024 indicates a startling 102% year-over-year rise.1 At the core of this ecosystem are energetic innovation hubs, notably in the UK, Germany, and Switzerland, home to leading academic institutions, research labs, and significant incubators and accelerators.2 Compared to the United States, Europe generates over double the volume of scientific publications, and a good share of worldwide biotech patents originate here.3 

For every startup, but especially in the European market with its special mix of opportunity and challenge, growth and achieving scale are guiding stars. Based on my experience closely dealing with startups and SMEs, the most important obstacle these businesses encounter is a delicate balancing act between regulatory compliance, fundraising and collaborations with local institutions and experts. Success in this industry depends on a multimodal approach that needs to adeptly navigate all of its elements.   

Why the European Market Behaves as It Does 

So, what drives the unique dynamics of the European bio-startup market? 

To start, the European regulatory environment is arguably the most renowned. Each EU member state enforces its policies despite attempts to harmonize health technology assessments (HTA) across Europe, therefore generating a heterogeneous environment that requires careful regulatory preparation from the outset.2,4 For instance, a startup creating a novel gene therapy with EU aspirations must navigate both the EMA’s centralized procedure and individual national HTAs. Following Brexit, the UK created its own regulatory system, led by the MHRA and NICE, which contains novel features such as the Highly Specialised Technologies Programme for quicker evaluations and a severity modifier for cost-effectiveness assessments. This difference obliges startups to use different registration and compliance approaches.5 

For businesses with limited resources, especially, the intricacy of the EU regulatory framework may extend deadlines and escalate costs. However, unlike the more isolated and smaller UK segment, the possible reward consists of access to a large, unified market. 

The second most notable aspect is the cautious investing environment. Usually more risk-averse than their US counterparts, European investors choose projects with clear success potential and little risk. Startups following this strategy find themselves mostly dependent on non-dilutive financing sources such government loans and EU subsidies.6 These funding sources impact the growth path of European bio-startups in unique ways even while they offer necessary early-stage money. 

Similarly more orientated on risk reduction than on encouraging high-risk, high-reward technologies, are public funding policies in Europe. This conservative approach can impede innovation since bio-startups could find it difficult to get the required capital to grow rapidly. Late-stage financing often lags behind US levels, which drives European businesses to look for significant growth capital from American markets.2,3 

Third, Europe faces a talent gap in dynamic fields that are meant to bridge biotech and business development. While notoriously having a strong foundation of research and development talent, Europe struggles with lower wages and difficulties in recruiting and retaining professionals experienced in both biotech and business. This gap can seriously impede businesses’ ability to scale and innovate, therefore complicating their path of development and the transition from lab research to market-ready products. 

Lastly, Europe’s different corporate cultures and regional competitiveness call for a customised strategy to market launch. Startups have to negotiate different business environments, usually needing local knowledge and connections to effectively enter individual markets. Europe’s diverse landscape consequently is a two-edged sword: it offers a rich basis for innovation but also presents major difficulties in realising this possibility for commercial success.  

Navigating the Choppy Waters 

Driven by its great research base, creative energy, and growing availability of early-stage financing, Europe remains a rich field for bio-startups despite these many obstacles. Success in this industry depends on a comprehensive plan including multiple strategies to skilfully handle this interplay of elements. Here’s a potential toolset for navigation: 

  • Diversify Your Funding: Blend traditional venture capital with non-dilutive options. Think about hybrid funding sources combining government grants with corporate venture capital (CVC) and venture capital itself. Supported by parent firms, CVCs such as Novartis Venture Fund, M Ventures and Sanofi Ventures provide not only strategic alignment and access to significant resources and market channels but also financial support. 
  • Forge Strategic Alliances: Larger company partnerships give access to market data, research resources and sophisticated technologies. High-profile agreements like Novo Nordisk’s $1.1 billion acquisition of Cardior and AstraZeneca’s $1.05 billion purchase of Amolyt Pharma, underline how important these relationships are in propelling development and achieving scale.1 
  • Embrace Innovation: Research and development processes can be greatly improved by artificial intelligence and machine learning; they can help to simplify operations, save costs, and expedite the route from research to market. Companies such as MultiOmic Health are using artificial intelligence to transform clinical research. Being competitive as a founder depends on using such technologies. 
  • Tap into Public-Private Synergies: Initiatives such as the Circular Economy Action Plan and the European Bioeconomy Strategy help government agencies and businesses to form partnerships. Since these alliances are especially successful in pooling resources and expertise from several industries to achieve thorough and sustainable development, they offer significant support in terms of funding, research cooperation, and market access. 
  • Build Your Network: In the European biotech scene, your network is your net worth. The best venues for presenting ideas and creating relevant connections are founders’ events, Startup gatherings, pitch contests or, if you are not short on budget, industry events, trade shows, and conferences. Participating in dedicated networks and industry associations provides ongoing support as well as assets that are vital for market entry and expansion. 
  • Navigate Cultural Waters: Create a culturally sensitive approach to business development and relationship-building. This could include funding cultural training for your staff or working with local professionals. What is effective in Berlin might not be in Barcelona or Bucharest. 
  • Invest in Talent Development: Close the talent gap by working with academic institutions to establish co-op and internship programs, therefore generating a pool of qualified experts. Use remote talent and engage consultants or freelancers for specific expertise without long-term commitment. Engage in accelerator programs providing access to mentoring and expert networks. Using online courses and certificates, encourage your team to upskill to stay updated with the most recent biotech and business developments. 

Charting Your Course to Success 

The European bio-startup ecosystem requires a blend of scientific brilliance and business acumen wrapped in a thorough awareness of the European context. Remember as you navigate these waters that every difficulty in this environment has a corresponding opportunity. The stringent regulations push you towards excellence. The cautious attitude towards investments inspires creativity in financing. The diverse market teaches you to think globally from day one. 

Although the path may be challenging, bio-startups can not only negotiate their way into the European market but also significantly influence the worldwide biotech scene with a well-defined plan and flexible attitude. Success in this ecosystem is found in the capacity to be creative, cooperative, and strategically move within the unique dynamics of the European market, thereby transforming its complexity into a competitive advantage.

About the author

Francesco Pappalardo, PhD
Biotech & Operations Subject Matter Expert

Francesco Pappalardo, PhD, is an experienced life sciences professional adept in biotech and MedTech innovation. Specializing in product management and strategic fundraising, he effectively communicates value propositions to stakeholders and investors. His expertise includes driving product ideation and lifecycle management, securing significant grants, fostering industry collaborations and leveraging Lean practices to deliver impactful customer-centric solutions.

Linkedin
Go back to the Magazine

Subscribe Now to the Bio-Startup Standard

Notify me for the next issue!

    Clinical adoption of AI-based products in lung cancer screening: barriers to market entry, and a comparative, multi-center, cross-European study. 

    Lung Cancer is the second most common type of cancer and the number one cause of cancer death. The majority of patients diagnosed with lung cancer are already in the late stages and, therefore, have a poor prognosis with a five-year survival rate of only 10–20%. Diagnosing lung cancer at an early stage, before the cancer has metastasized, could increase the chance of providing effective treatment earlier and the survival rates dramatically. Two large RCTs have clinically proven that annual screening of the risk population through Low-dose CT (LDCT) reduces mortality by approximately 20%; the US-based, NCI-initiated NLST study and the European NELSON study, initiated by i-DNA, a Dutch research organization, dedicated to early detection of lung cancer. This positioned i-DNA and their scientific leader, Professor Matthijs Oudkerk, as the leading global group in the field. Based on these two studies, the use of LDCT has been recommended by health organizations worldwide. Countries throughout the world have begun to either adopt screening programs or are in screening programs pilots, like the Israeli Ministry of Health TIGAR program.  

    One of the hurdles to the full adoption of the screening programs is the radiologist’s bottleneck, which is severe and only aggravating worldwide. Screening of lung cancer requires the interpreting radiologist to go over several hundreds of slides in the chest CT scan and detect each cancer suspicious “Lung nodule” – tiny objects the size of several millimeters, with the characteristics of probability of developing into cancerous tumors. This tedious work consumes a lot of time and effort and is subject to inter and intra-observer variability as well as human error. 

    Given all these factors, the need for using AI-based tools to detect and manage lung nodules is clear. Indeed, there are publications confirming the good performance of AI in the detection, segmentation, and classification of nodules, and in LCS, AI as an impartial reader exceeds radiologists in negative misclassification results and reduces workload by up to 86.7%. And still, despite the clear need and the promising results, real clinical implementation is rare. Therefore, i-DNA, as the leading global organization promoting the implementation of screening programs, has initiated a new strategic project. Recognizing the barriers to adoption as the limited clinical evidence, lack of multi-center studies, and limited cost-effectiveness data, resulting majorly from the technological limits current AI technologies are bound to, as well as the need to create a benchmark of AI solutions to empower purchasers to make better-informed decisions, they have created a large comparative study between the leading AI models in the world. The project involves the two most important screening programs in Europe, 4ITLR and UKLS, with data gathered from leading medical centers in 8 countries. The project aims to generate the exact needed clinical and economic data to allow real implementation of AI technology in LCS and in the radiologists’ real-life clinical workflow. 

    Genesis Medical Vision is an Israeli company developing an early detection of cancer AI platform. The company is pioneering deep IIMM technology, a completely new and different approach to AI in radiology, which allows the company to imitate and replicate the logic and intuition of physicians and build an algorithm accordingly. Thanks to that unique approach, the company believes it can solve all the technological barriers that have delayed and prevented the adoption of AI technology in the market until now. Genesis has finalized a clinical trial with its first product, the G4Lungs, allowing automated screening of lung cancer together with its design partner Assuta, showing results that facilitate real clinical adoption. The next step is to prove all these claims on a larger scale clinically, in a comparative study, and on the most important stage in the world. 

    Genesis has partnered with i-DNA and is participating in this exclusive comparative study, which should pave the way towards the market and real clinical adoption in Europe but also in other strategic markets, such as the US.  

    About the author

    Shay Cohen
    CEO & Co-founder of Genesis Medical Vision

    With vast business development, strategy, and execution experience, Shay is a proficient healthcare leader, experienced in turning raw ideas into products, and taking them onto global markets. 

    Linkedin
    Go back to the Magazine

    Subscribe Now to the Bio-Startup Standard

    Notify me for the next issue!

      The Europe Issue: Challenges and Opportunities for Bio-startups

      Welcome to the second issue of our online magazine, where we explore the dynamic and diverse landscape of European biotech and healthcare innovation. Our goal in this edition is to equip you with a foundational understanding of the European biosciences ecosystem, while also offering a wide range of perspectives and strategic insights that can help you navigate this complex yet opportunity-rich environment. 

      Europe presents a unique set of challenges and opportunities for bio-startups and established players alike. In this issue, we delve into the critical aspects of operating within this market, from understanding the regulatory intricacies of clinical trials to the importance of maintaining a robust clinical supply chain. These are not just technical details—they are essential elements that can significantly impact your success in this region. For instance, our exploration of temperature-controlled logistics highlights how vital it is to ensure the integrity of investigational medicinal products across Europe’s varied climates and regulatory environments. 

      One of the standout features of this issue is our deep dive into the German Digital Health Applications (DiGA) initiative. This program, which allows digital health applications to be prescribed by doctors and reimbursed by health insurance, exemplifies the innovative pathways unique to Europe. By understanding and leveraging these opportunities, companies can gain a significant competitive edge in the market. 

      Our magazine is designed to be eclectic, providing you with a diverse array of points to consider, whether you’re a startup founder, an investor, or a seasoned industry professional. We cover everything from the differences in investigational product labeling requirements between the US and EU to the evolving interpretation of “second medical use” exceptions in patent law. These insights are more than just compliance guidelines—they are strategic advantages that can help you position your company for success in the European market. 

      The uniqueness of the European market lies not only in its regulatory complexities but also in the vast opportunities it holds. Europe’s diverse ecosystem offers significant advantages, such as access to a large, unified market, but it also demands a deep understanding of its challenges. The personal experiences and expert opinions shared by our contributors in this issue underscore the importance of a well-rounded approach that blends technical expertise with strategic insight. 

      As you read through this issue, I encourage you to reflect on the opportunities that Europe offers. Whether you are new to the market or looking to expand your presence, the knowledge and strategies presented here are designed to support you in making informed decisions. We hope that these insights will inspire you to embrace the challenges, seize the opportunities, and ultimately make a lasting impact in the European biosciences landscape. 

      Thank you for joining us on this journey through the European biotech ecosystem. Here’s to the breakthroughs, collaborations, and successes that await us all in this vibrant and ever-evolving market. 

      Warm regards,   

      Roy 

      About the author

      Roy Zaibel
      Editor at The Bio-Startup Standard and Co-CEO @ ADRES International Biotech Consultation and Execution

      Roy helps non-EU startup companies obtain their SME status

      Contact Roy by Mail: roy@adres.bio

      LinkedinProfile
      Go back to the Magazine

      Subscribe Now to the Bio-Startup Standard

      Notify me for the next issue!

        The Bio-Startup Standard Crosswords

        Magazine shortcode is available only on magazine page
        Go back to the Magazine

        Subscribe Now to the Bio-Startup Standard

        Notify me for the next issue!

          The Tech Transfer Issue: Bridging Innovation and Industry

          In the pharmaceutical world, Technology transfer (TT) is part of the product’s lifecycle. TT refers to the process of transferring knowledge, technologies, and methodologies from one institute or facility to another. This broad definition encompasses various activities, from moving academic discoveries to the commercial sector to sharing innovations between different companies or research facilities.

          In this issue of The Biotech Startup Standard, we cover several key aspects of technology transfer:

          1. Operational Aspects: Explore the critical steps involved in the technology transfer process, ensuring smooth integration and reproducibility in a new setting. “Technology transfer is the exchange of technical information between the R&D workers who create a technological innovation and the users of the new idea”.
          2. Risk Management: Delve into strategies to minimize risks associated with technology transfer, focusing on best practices and risk-free approaches. According to a detailed discussion, “Tech transfer making it as a risk-free approach in pharmaceutical and biotech industries involves extensive planning and validation”.
          3. Best Practices: Learn about the systematic approaches and frameworks that facilitate effective technology transfer and scale-up, ensuring successful transitions. The systematic approach is essential as “a well-executed bioprocess technology transfer (tech transfer) is critical to ensure smooth knowledge transfer and optimal process reproducibility”.
          4. Real-Life Examples: Discover real-life examples of successful technology transfers, highlighting common challenges and solutions to inspire and guide your own efforts. As stated, “Effective transfer of biotechnologies enables these developing countries to utilize their natural and human resources efficiently”.

          Our articles provide snapshots of these essential topics, offering insights and practical advice for biotech startups. Dive into this issue to uncover detailed discussions, expert opinions, and success stories that will equip you with the knowledge and tools needed to navigate the complexities of technology transfer.

          About the author

          Rivka Zaibel
          President and Founder @ ADRES International Biotech Consultation and Execution

          With over 35 years in biopharmaceutics and biotechnology, Ms. Zaibel has led an impressive number of multidisciplinary projects, supports startups globally, and has secured FDA and EMA approvals for recombinant proteins, vaccines, and medical devices. In 2019-2020, Ms. Zaibel joined the Weizmann Institute of Science SPARK project as a mentor and also became a member of the advisory board and lecturer for a new Master's degree in Regulatory and Drug Development at TAU. In 2022, the ADRES team led by Ms. Zaibel joined the BIODESIGN ISRAEL Rambam healthcare campus program as mentors. In 2023, Rivka was accepted as a mentor by EIT Health.

          Linkedin
          Go back to the Magazine

          Subscribe Now to the Bio-Startup Standard

          Notify me for the next issue!

            Introducing The Biotech Startup Standard

            Welcome to the inaugural issue of The Biotech Startup Standard, your premier source for insights and guidance in the development of new medicinal products. The idea for this magazine came to me during a brainstorming session between us at ADRES and a few industry colleagues over coffee. We realized there was a gap in accessible, practical information for biotech startups navigating the complex journey from concept to market. I reached out to several writers and experts in the field, and to my delight, they were enthusiastic about contributing their knowledge and experiences. Their cooperation has been invaluable in bringing this magazine to life.

            Life science startups face numerous challenges, with the three biggest being:

            1. Scientific Issues: Determining whether the technology works and has a viable therapeutic effect is paramount. This involves rigorous research and development to ensure the product’s efficacy and safety.
            2. Funding: Securing capital is a constant challenge for early-stage biotech ventures. Adequate funding is essential to support research, development, and eventual commercialization.
            3. Regulatory: Navigating the complex landscape of regulatory requirements is crucial for bringing a product to market. Compliance with stringent regulations ensures that the product meets all necessary safety and efficacy standards.

            The Biotech Startup Standard is dedicated to addressing these challenges head-on. Our quarterly issues, each dedicated to a specific topic, will provide biotech startups with the latest trends, expert advice, and success stories from the world of medical innovation.

            Join us as we embark on this journey to transform innovative ideas into life-saving solutions!

            About the author

            Roy Zaibel
            Editor at The Bio-Startup Standard
            Linkedin
            Go back to the Magazine

            Subscribe Now to the Bio-Startup Standard

            Notify me for the next issue!

              The Founder’s Perspective: Building Trust and Identifying Gaps for Successful Technology Transfer

              From my experience as a biotech startup founder, the technology transfer (TT) process involves due diligence and relationship building with the principal investigator (PI) and lab members, the Tech Transfer Office (TTO), Or an incubator’s management team. Most times, things don’t go as smoothly as expected, and this article will focus on what can be done in advance to avoid or minimize the gaps. Remember: Both sides of the tech transfer share the same goal of drug/therapy/product development at best! The main pillars for a successful TT are:

              • Get prepared and learn all the details
              • Maintain a respectful attitude
              • Employ critical thinking
              • Come with humbleness

              Technology Transfer (TT) is done after a deal or agreement is set. The process can be divided into three main parts:

              1. Before the tech transfer
              2. The tech transfer process
              3. Ongoing relationships during the development journey

              1. Before the tech transfer process

              The goal is to evaluate gaps, raise questions, and look for data inconsistencies or contradictions in the literature. Prepare thoroughly based on literature, the web, AI tools, and the licensing agreement.

              • Read the licensing agreement carefully. Understand your duties and responsibilities
              • Evaluate the IP
              • Delve into the literature

              Approach the Principal Investigator while CCing the TT representative, legal representative, and one board member of the company. Write an engaging intro email and set up an intro meeting. Tailor the TT visit agenda, map the topics and relevant people to meet, and build the schedule with the Principal Investigator or Lab research associate. Allocate time for your presentation and self-introduction, the first cornerstone of building trust. Don’t come alone. Bring a team member, consultant, or an unbiased person proficient in TT. Here is the agenda I prepared for the TT from UCLA lab.

              Visit:

              https://docs.google.com/document/d/141nKzbpeRXOcJ3WAPKCLSO6Wgj8MNJ-E/edit?usp=sharing&ouid=100548261671423884368&rtpof=true&sd=true

              2. The tech transfer process

              Goal: Build trust and rewrite the strategy and development plan based on the tech transfer.

              Now that the visit agenda is ready, get super prepared and navigate the schedule professionally while applying the following pillars: Documentation and organization, transparency, and trust.

              Building trust with power skills: Respect the work done, the findings, and the efforts behind them. Come humbly, ask questions, listen, and remember that this interaction is for the long-term, and relationship building is essential. Avoid “educating” the lab members. Process what can be done and what can’t, and to what extent.

              It is essential to list the responsibilities of each party and prepare an agenda for the visit in advance. Talk with those who practically did the work. Ask for every detail.

              Communicate mainly about what didn’t work since this precious knowledge is hidden and can save you time and effort in your development endeavors.

              Document every piece of data that needs to be sorted out further. Create a “live” document of the topics covered, gaps, and things to fill.

              Zoom out and re-evaluate your development plan, strategy, and milestones. If major gaps are found–rewrite the strategy and development plan, find creative solutions, and adapt the budget plan for needed tasks. Prepare a summary document or presentation and communicate it with the Board of Directors.

              You are ready to go!

              3. Ongoing relationships during the development journey

              Goal: joined collaboration for fruitful processes–take proactive actions to keep the interaction alive:

              • Set periodic update meetings but be aware of IP generated and their contribution within the limitations of the academic institute and the licensing agreement.
              • Share information of interest related to the field with the PI and associate researcher, such as publications, deals, companies, and market trends.
              • Consider writing a joint paper or grant.
              • Ask the PI for relevant contact KOL persons in the field: physicians, clinicians, organizations, etc.
              • Optional: Get the lab members involved but remember each party’s responsibilities and the differences between academia and industry

              In summary, successful technology transfer requires thorough preparation, a respectful attitude, critical thinking, and humility. By evaluating gaps, raising questions, and building trust through transparency and effective communication, founders can bridge the gap between academia and industry. The key is maintaining an ongoing relationship, sharing insights, considering collaborative opportunities, and remembering that both parties aim to advance drug, therapy, or product development.

              About the author

              Dorit Cohen Carmon PhD
              Biotech Leadership

              Dorit Cohen Carmon is a proficient biotech leader experienced in establishing and managing companies in various therapeutic areas. She brings Strategic vision, planning, and execution for integrating R&D, legal, and BD aspects. She received her Ph.D. from WIS and was awarded a Teva Post-Doctorate fellowship. Dorit's motivation is to translate scientific technologies into therapies and connect people for value creation.

              Linkedin
              Go back to the Magazine

              Subscribe Now to the Bio-Startup Standard

              Notify me for the next issue!

                Technology Transfer Companies: Turning Academic Research into Tangible Solutions and Startup Companies

                Technology transfer companies play a crucial role in translating groundbreaking research into practical solutions that benefit society. They serve as bridges between academia and industry, facilitating the transformation of theoretical discoveries into marketable products and services.

                Ramot, established in 1973a subsidiary of Tel Aviv University Ltd. is the Tech-Transfer company of Tel Aviv University, responsible for commercializing the inventions and patents of the university’s researchers. It manages all the university’s commercialization activities, from protecting the intellectual property of researchers’ inventions to licensing them to relevant industrial entities. The company fosters and creates new business opportunities at the university, such as establishing startups, licensing technology to existing companies – both Israeli and multinational – and creating collaborations with these entities.

                Since its inception, Ramot has filed over 5,000 patent applications and maintains a portfolio of approximately 1,600 patent applications and patents. Ramot signs dozens of commercial agreements each year and is involved in the establishment of approximately 100 startups.

                Startup establishment is a central strategy employed by Ramot to promote technologies. When a technology requires further development, Ramot facilitates fundraising, identifies suitable entrepreneurs, and collaborates with venture capital funds, incubators, and other organizations that support entrepreneurs. This collaboration equips entrepreneurs with the tools and support they need for startup success. For instance, Ramot has successfully nurtured two notable startups:

                Alpha Tau: Established in 2015, based on the technology of Prof. Yona Keisari and Prof. Itzhak Kelson. Alpha Tau is a clinical-stage oncology company developing a novel radiotherapy technology for treating solid tumors. The company’s technology aims to address the limitations of conventional radiation therapy by minimizing side effects and improving treatment efficacy. In 2022, Alpha Tau merged with SPAC at a valuation of approximately $1 billion and began trading on the Nasdaq. The company recently conducted its first clinical trial in prostate cancer patients.

                Imagindairy: Founded in 2020, Imagindairy is a biotechnology company based on Prof. Tamir Tuller’s technology. It is developing a sustainable and scalable process for producing cultivated dairy products using precision fermentation. Leveraging artificial intelligence and systems biology, Imagindairy’s technology utilizes microorganisms to create milk proteins identical to those found in cow’s milk. As of 2022, the company has raised approximately $28 million in funding.

                At the heart of Ramot’s success in nurturing tech transfer startups lies its close collaboration with researchers. Ramot actively engages with researchers throughout the innovation cycle, from ideation to commercialization. This deep understanding of the research landscape and the challenges faced by researchers enables Ramot to identify promising technologies with commercial potential and provide tailored support to transform them into viable startups.

                The company’s collaborative approach extends to identifying and attracting talented entrepreneurs. Ramot works closely with researchers to identify individuals with the technical expertise, business acumen, and leadership skills necessary to successfully lead tech transfer startups. By fostering strong relationships with both researchers and entrepreneurs, Ramot creates an environment conducive to innovation and startup growth.

                To navigate the ever-changing technological landscape, Ramot adopts innovative strategies. It allocates resources to identify emerging technological trends and participates in international conferences and events. These activities enable Ramot to recognize new opportunities for technology transfer and establish international partnerships.

                In conclusion, Ramot plays a pivotal role in commercializing groundbreaking research from Tel Aviv University. By supporting researchers, establishing startups, collaborating with venture funds, incubators, accelerators, and entrepreneurs, and fostering a culture of close collaboration with researchers, Ramot contributes to Israel’s economy and enhances our lives through novel technologies.

                You can find more information on the Ramot: www.ramot.org

                About the author

                Tali Aloya Ph.D.
                VP Business Development, Life sciences at Ramot at Tel Aviv University Ltd

                Dr. Tali Aloya is a seasoned Life science executive with over 20 years of experience, including roles as CEO of BioRap Technologies and IP director at High Jump Pharma. She currently leads the Life Sciences Business Development at Ramot, Tel Aviv University, and holds a PhD in Biological Chemistry from The Hebrew University of Jerusalem

                Linkedin
                Go back to the Magazine

                Subscribe Now to the Bio-Startup Standard

                Notify me for the next issue!

                  Assessing the Market Need for a New Idea in Healthcare

                  In the ever-evolving field of healthcare, bringing a new idea to fruition involves a meticulous understanding of the market need. Whether it’s a new drug, a revolutionary medical device, a healthcare app, or a unique service model, the success of such innovation hinges on its relevance and demand within the healthcare market. Here’s a structured approach for assessing the market need for a new idea in healthcare:

                  Step1: Define Your Idea

                  Begin by clearly defining the value of your healthcare innovation:

                  • What problem does it solve?
                  • Define the clinical condition or medical indications it solves best.
                  • How does it improve over existing solutions?

                  If your idea can be used to treat several conditions, choose the one that is of utmost need. Establish clear objectives for the design of your idea, based on the defined unmet needs.

                  Step 2: Conduct Comprehensive Market Research

                  Healthcare market research is a systematic process that involves ongoing collection, analysis, and interpretation of data related to the healthcare industry. It helps in understanding market dynamics, consumer behavior, and competitive landscape. Remember, since it takes a long time to reach the market, market research should be updated regularly.

                  Step 3: Analyze Market Size,Growth and Structure

                  Understanding the size and growth rate of the healthcare market, including specific segments relevant to your idea, is crucial. It is also important to learn how the market is structured: who are the critical players, who controls what segment (including HMOs, government, etc.).This analysis helps identify the potential and scalability of your innovation.

                  Step 4: Gather Consumer Insights

                  Gaining insights into consumer behavior, preferences, and needs is essential. This involves collecting data on patient demographics, healthcare personnel approach to the idea, healthcare utilization patterns, to assist in the development of patient-centric solutions.

                  Step 5: Competition

                  Search for competitor or existing solutions, even if they are not similar. Assessing your competitors’ products, pricing, distribution channels, and marketing strategies provides a benchmark and helps you plan your offering effectively in the market.

                  Step 6: Consider Regulatory Environment

                  Healthcare is heavily regulated. Staying informed about regulatory changes and ensuring compliance is vital when developing and introducing new healthcare products or services. Follow the regulatory agencies of the markets you wish to reach regularly. Learn about their approval of products for the same intended uses.

                  Step 7: Test Market Acceptance-clinical trials

                  Before a full-scale launch, testing your idea through pilot studies or focus groups can provide valuable feedback on market acceptance and potential areas for improvement. Clinical trials are compulsory for some products, like drugs and high-risk medical devices. Some products can get approval without clinical trials, but marketing and commercializing will almost always require them in healthcare. Learn the process and seek expert advice.

                  Step 8: Plan for Market Entry and Expansion

                  Assess the feasibility of entering new markets or expanding operations. This includes understanding local healthcare systems, reimbursement mechanisms, and customer preferences.

                  Conclusion

                  Assessing the market need for a new healthcare idea is a complex but critical process. It requires a deep dive into market research, consumer understanding, and competitive analysis. By following these steps, healthcare innovators can significantly increase the chances of their idea’s success in the market.

                  Tips: Looking for competitors

                  • check for sponsors of clinical trials for the defined indication in www.clinicaltrials.gov
                  • check patents database, using search topics such as indications, diseases, devices, names of sponsors, names of scientists in the field etc. www.espacenet
                  • seek expert advice–the path to the market is long, expensive and success rate is low.

                  About the author

                  Michal Roll PhD , MBA
                  Health-Tech Consultant

                  Dr. Michal (Micki) Roll is an experienced healthcare and business development professional. She holds an MBA, PhD in Medical Sciences (Pharmacology) with a Post Doctorate in Neurobiology and training in IP protection.
                  Micki was the Deputy Director General of R&D at Tel Aviv Medical Center (TASMC) and CEO of its tech. transfer R&D co. She had previously served as the Director of the Research Department of Hadassah Medical Organization.

                  Micki is co- director of the MSc program: “Therapeutics development and Regulatory Science” the Faculty of Medical & Health Sciences, Tel Aviv University  and consultant to the Ministry of Health

                  Micki is a member of the 8400 health network.

                  michalroll@gmail.com +972-524266006

                  Linkedin
                  Go back to the Magazine

                  Subscribe Now to the Bio-Startup Standard

                  Notify me for the next issue!

                    Early Market Access Planning for Successful Commercialization of Healthcare Innovations in the USA

                    There are many considerations to account for, both prior to and during the development of any new healthcare solution or innovation. Proactive steps such as performing market research, assessing competitors, and developing a strategy to comply with country-specific regulatory requirements are very important and well-established. If the strategic plans for your offering include making your innovation available in the United States market, it is critical to assess and define a cohesive and complementary market access strategy to maximize your chances of successful market entry and adoption.

                    Market Access in the US

                    The US healthcare system continues to undergo rapid transformation. The number of impactful innovations coming to market continues to grow at an accelerated pace. Competition is fierce, raising capital is challenging, and those who don’t account for market access considerations early in the development process are more likely to struggle. US market access can be defined as the intersection three score, interdependent categories:

                    1. Reimbursement-pricing, coding, coverage & payment
                    2. Value proposition–evidence showing the clinical, economic, quality of life(QoL) impact on patients, clinicians, payers, and society versus competitors and standard care
                    3. Payer access–medical policy and payment from government & private insurance companies, health systems, self-insured employers

                    Important Questions to Consider

                    Is there (what is) a viable reimbursement pathway to payment for your solutions from Medicare and private health insurance plans? Is there a code I will need for payment from insurers? Will I need a new code, or can I use an existing code? What are the requirements to obtain a new code? What is the value (clinical, economic, quality of life improvements) your solution can bring to patients, physicians, and insurance companies in the US versus competitors and/or standard care? How does your innovation improve patient outcomes, change physician treatment protocol? Is your solution cost-effective? What is the budget impact on payers? (How) does it improve patient experience? Which payers should you target? What do payer Medical Directors think are the most important areas for which to define and illustrate value for your specific innovation? What is your evidence and publication strategy to illustrate this value to various stake holders in the US healthcare ecosystem? Can you (how can you) incorporate various endpoints into your clinical trial design? What other studies will you need? What other tools will be necessary to show value? How will you price and justify the pricing for your solution in the US?

                    Whether your innovation is a diagnostic test, medical device, digital platform, SaaS or a therapeutic, assessing and establishing market access pathways early in the development process, combined with thorough market research and a well-defined regulatory approach (when applicable) will maximize the opportunity to drive successful market entry and adoption for your innovation. The author is a visionary market access leader with extensive experience in health technology reimbursement, value creation, and payer access.

                    www.dreambighealth.org

                    About the author

                    Darron Segall, MHS
                    Managing Partner & Co-Founder DREAM BIG™ Health

                    The author is a visionary market access leader with extensive experience in health technology reimbursement, value creation, and payer access. Darron, who recently emigrated to Israel, is co-founder and managing partner of Dream Big Health. www.dreambighealth.org

                    Linkedin
                    Go back to the Magazine

                    Subscribe Now to the Bio-Startup Standard

                    Notify me for the next issue!

                      Contact Us
                      Contact us







                        Skip to content